HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis

Company Overview

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Key Stats

• Today's Range: N/A
• 50-Day Range: $5.01 to $6.80
• 52-Week Range: N/A
• Volume: 773,040 shs
• Average Volume: 294,806 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HTGM Stock Analysis - Frequently Asked Questions

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.60). The medical research company earned $2.52 million during the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a positive trailing twelve-month return on equity of 45.52% and a negative net margin of 324.25%.

When did HTG Molecular Diagnostics IPO?

HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HTG Molecular Diagnostics investors own include Sangamo Therapeutics (SGMO), Idera Pharmaceuticals (IDRA), NightHawk Biosciences (NHWK), Abeona Therapeutics (ABEO), Exelixis (EXEL), Bionano Genomics (BNGO) and Adamis Pharmaceuticals (ADMP).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HTGM
• CIK: 1169987
• Web: www.htgmolecular.com
• Phone: (520) 547-2827
• Fax: 520-547-2837
• Employees: 84
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.59 million
• Net Margins: -324.25%
• Pretax Margin: -324.05%
• Return on Equity: 45.52%
• Return on Assets: 8.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.40
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: $6.37 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.44 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,210,000
• Free Float: 2,156,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: 0.99